Abstract
The progressive loss of skeletal muscle mass and function is frequently observed in elderly and patients with chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD). This may lead to sarcopenia, which affects physical functioning and metabolic health. The prevention and treatment of sarcopenia requires a better understanding of the underlying cellular and molecular pathobiology.
Although skeletal muscle catabolic processes have been broadly studied, a potential role for impaired skeletal muscle recovery in the development of sarcopenia is still underexplored. In this thesis, we therefore set out the development and use of novel strategies for the assessment of molecular disturbances in the regulation of skeletal muscle mass and quality in COPD patients, and discuss the implications for the development of COPD-related muscle pathology.
Defence date: 21/12/18
Institut NeuroMyogene